Stock Movers

On this episode of Stock Movers:- Novo Nordisk (NVO) shares rallied in trading today following the drugmaker getting US approval to sell a pill version of its blockbuster obesity shot Wegovy. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term. The pill is crucial for Novo’s strategy to take on Eli Lilly, which has said its own oral obesity drug could be approved by March. That would give Novo a head start of just a few months. - ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. The Santa Clara, California-based enterprise tech company will pay in cash for San Francisco-based Armis, according to a statement Tuesday that confirmed an earlier Bloomberg News report. ServiceNow, which provides software that helps companies organize and automate their personnel and information technology operations, has become a dominant platform for enterprise workflow. In March, ServiceNow struck an agreement to buy the artificial intelligence firm Moveworks Inc. for $2.85 billion as part of its push into AI tools that can complete tasks without human supervision. Shares of the startup fell during trading on Tuesday.- Sable (SOC) shares rose as much as 30% after the company said that the US Department of Transportation, Pipeline and Hazardous Materials Safety Administration approved the firm’s Las Flores pipeline restart plan.See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:- Novo Nordisk (NVO) won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly. The shares soared by as much as 11% in Copenhagen, the biggest intraday gain since August. Novo has fallen by almost half this year amid concern about the Danish drugmaker’s ability to compete in the obesity market it pioneered. Shares continued to rally in New York trading on Tuesday.- Johnson & Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company’s talc-based baby powder for causing her asbestos-linked cancer, the largest such verdict for an individual in 15 years of litigation. The verdict comes as J&J has been pummeled by a recent spate of baby powder verdicts after it failed this year to use bankruptcy court to force a settlement of more than 70,000 lawsuits accusing the company of hiding the product’s cancer risks. Shares of the company fell in trading on Tuesday.- ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. Shares in ServiceNow fell about 1.3% in early trading before markets opened in New York. They closed up around 0.9% on Monday, giving the company a market valuation of about $163 billion.See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:- Novo Nordisk (NOVOB) won approval to sell a pill version of its obesity shot Wegovy in the US, to help people lose weight or maintain previous weight loss over the long term. The company will start selling the pill in the US in early January, and it is approved based on the results of the Oasis 4 trial, which found people taking the pill lost about 13.6% of their body weight over 64 weeks.- Johnson & Johnson (JNJ) was ordered to pay about $1.56 billion to a Maryland woman who blamed the company's talc-based baby powder for causing her asbestos-linked cancer.- ServiceNow Inc. has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. Shares have fallen over 4% on the news.See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:- Novo Nordisk (NOVOB) won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly (LLY). The shares soared by as much as 11% in Copenhagen, the biggest intraday gain since August. Novo has fallen by almost half this year amid concern about the Danish drugmaker’s ability to compete in the obesity market it pioneered.- Copper hit a fresh all-time high above $12,000 a ton due to severe mine outages and trade dislocations linked to US President Donald Trump’s tariff agenda. Shares of Albemarle climbed as a result. - The US Navy announced plans to build a new class of warship, the FF(X), as part of President Donald Trump's "Golden Fleet" bid to revive US shipbuilding. That caused shares of Huntington Ingalls Industries Inc. to rise.See omnystudio.com/listener for privacy information.

On this episode of Stock Movers:- Shares of Novo Nordisk (NVO) soared in premarket trading after the company won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly & Co. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term.- Shares of naval shipmaker Huntington Ingalls (HII) rallied ahead of the US market open after President Trump announced the Navy will build a new “Trump-class” battleship as part of the White House push to modernize a fleet that’s been hobbled by years of cost overruns and delays.- Shares of Copenhagen-listed Orsted (ORSTED DC) declined after the company said it’s considering “all options” including legal action as it weighs how to respond to a US decision to suspend leases for five offshore wind farms, according to a statement late Monday. Orsted said its farms — Revolution Wind and Sunrise Wind — had secured all the required federal and state permits, including consulting “closely and directly” with US authorities to “to evaluate and address potential impacts to national security and defense capabilities.See omnystudio.com/listener for privacy information.